
浏览全部资源
扫码关注微信
1.河北省中医院,石家庄 050011
2.河北省中医学院,石家庄 050200
许梅,硕士,主治医师,从事中医重症诊治工作,E-mail:340181762@qq.com
施保柱,副主任医师,从事中医重症诊治工作,E-mail:shbzh0088@163.com
收稿日期:2022-07-12,
网络出版日期:2022-12-02,
纸质出版日期:2023-04-05
移动端阅览
许梅,段明明,杨明华等.祛瘀解毒利水法(血必净和加味苓桂术甘汤)辅助治疗对脓毒症心肌病患者预后的影响[J].中国实验方剂学杂志,2023,29(07):146-152.
XU Mei,DUAN Mingming,YANG Minghua,et al.Therapy of Dispelling Stasis, Removing Toxin, and Promoting Urination (Xuebijing Injection Combined with Modified Linggui Zhugantang) Affects Prognosis of Sepsis-induced Cardiomyopathy[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(07):146-152.
许梅,段明明,杨明华等.祛瘀解毒利水法(血必净和加味苓桂术甘汤)辅助治疗对脓毒症心肌病患者预后的影响[J].中国实验方剂学杂志,2023,29(07):146-152. DOI: 10.13422/j.cnki.syfjx.20231396.
XU Mei,DUAN Mingming,YANG Minghua,et al.Therapy of Dispelling Stasis, Removing Toxin, and Promoting Urination (Xuebijing Injection Combined with Modified Linggui Zhugantang) Affects Prognosis of Sepsis-induced Cardiomyopathy[J].Chinese Journal of Experimental Traditional Medical Formulae,2023,29(07):146-152. DOI: 10.13422/j.cnki.syfjx.20231396.
目的
2
评价祛瘀解毒利水法(血必净和加味苓桂术甘汤)辅助治疗对脓毒症心肌病(SICM)患者预后的影响。
方法
2
将96例患者随机分为观察组和对照组,每组各48例。对照患者给予脓毒症集束化治疗;观察组在对照组的基础上给予祛瘀解毒利水法治疗(血必净注射液静脉滴注和加味苓桂术甘汤内服),两组疗程均为7 d。评估两组患者病情和预后评估指标[28 d死亡率,重症监护室(ICU)住院时间,主要不良心血管事件(MACE)、急性生理和慢性健康评分Ⅱ(APACHEⅡ)、脓毒症相关序贯器官衰竭评估(SOFA)评分、急诊脓毒症死亡风险评分(MEDS)]、心功能指标[左室射血分数(LVEF)、舒张早期二尖瓣血流速度/舒张晚期二尖瓣血流速度(E/A)、舒张早期二尖瓣血流速度/二尖瓣环舒张早期运动速度(E/e′)、后负荷校正心功能参数(ACP)]、心肌损伤标志[高敏心肌肌钙蛋白T(hs-cTnT)、N-末端B型脑钠肽前体(NT-proBNP)、心肌型-脂肪酸结合蛋白(H-FABP)、高迁移率族蛋白-1(HMGB-1)]、血流动力学指标[血管外肺水指数(EVLWI)、全心舒张末期容积指数(GEDVI)、心脏指数(CI)和外周血管阻力指数(SVRI)]及中医证候评分。
结果
2
与对照组比较,观察组28 d死亡率和MACE发生率均低于对照组,但差异无统计学意义;观察组ICU住院时间短于对照组(
P
<
0.05)。与本组治疗前比较,两组患者治疗后APACHEⅡ、SOFA、MEDS和瘀毒内阻证评分、E/e′、hs-cTnT、NT-proBNP、H-FABP和HMGB1均明显降低(
P
<
0.05),LVEF、E/A和ACP明显升高(
P
<
0.05);与对照组治疗后比较,观察组改善更明显(
P
<
0.05)。治疗后第3、5、7天,观察组患者EVLWI、SVRI低于对照组(
P
<
0.05),CI高于对照组(
P
<
0.05),在治疗后第3、5天,观察组GEDVI高于对照组(
P
<
0.05)。
结论
2
在西医常规集束化治疗的基础上,针对SICM病机特点进行祛瘀解毒利水法治疗,采用加味苓桂术甘汤联合血必净注射液辅助治疗,可抑制心肌损伤标志物、改善血流动力学,减轻了病情程度,缩短了ICU住院时间,减轻了中医证候,降低了死亡风险,有利于SICM预后的改善。
Objective
2
To evaluate the effect of the therapy of dispelling stasis, removing toxin, and promoting urination (modified Linggui Zhugantang combined with Xuebijing injection) on the prognosis of sepsis-induced cardiomyopathy (SICM).
Method
2
A total of 96 patients were randomly assigned into an observation group and a control group, with 48 patients in each group. The patients in the control group received sepsis bundle, and those in the observation group additionally received the therapy of dispelling stasis, removing toxin, and promoting urination (intravenous drip of Xuebijing injection and oral administration of modified Linggui Zhugantang). The course of treatment in both groups was 7 days. The disease and prognosis indicators [28-day mortality, intensive care unit (ICU) length of stay, major adverse cardiac events (MACE), acute physiology and chronic health evaluation Ⅱ (APACHE Ⅱ), sequential organ failure assessment (SOFA) score, and mortality in emergency department sepsis (MEDS) score], cardiac function indicators [left ventricular ejection fraction (LVEF), E/A ratio of peak velocity blood flow from left ventricular relaxation in early diastole (the E wave) to peak velocity flow in late diastole caused by atrial contraction (the A wave), E/e′ ratio of mitral peak velocity of early filling (E) to early diastolic mitral annular velocity (e′), and afterload-corrected cardiac performance (ACP)], myocardial injury markers [high-sensitivity cardiac troponin T (hs-cTnT), N-terminal pro-brain natriuretic peptide (NT-proBNP), heart-type fatty acid-binding protein (H-FABP), and high mobility group box-1 (HMGB-1)], hemodynamic indicators [extravascular lung water index (EVLWI), global end-diastolic volume index (GEDVI), cardiac index (CI), and systemic vascular resistance index (SVRI)], and TCM syndrome scores were assessed and compared between the two groups.
Result
2
The 28-day mortality and the incidence of MACE in the observation group were slightly lower than those in the control group. The ICU length of stay in the observation group was shorter than that in the control group (
P
<
0.05). After treatment, APACHE Ⅱ, SOFA, MEDS, syndrome score of stasis-caused internal obstruction, E/e′ ratio, hs-cTnT, NT-proBNP, H-FABP, and HMGB1 decreased compared with those before treatment (
P
<
0.05), while LVEF, E/A ratio, and ACP increased (
P
<
0.05). Moreover, the changes were more significant in the observation group (
P
<
0.05). On days 3, 5, and 7 after treatment, the EVLWI and SVRI in the observation group were lower than those in the control group (
P
<
0.05), while CI showed an opposite trend (
P
<
0.05). The observation group had higher GEDVI than the control group on days 3 and 5 after treatment (
P
<
0.05).
Conclusion
2
On the basis of conventional bundle therapy, modified Linggui Zhugantang combined with Xuebijing injection with the effect of dispelling stasis, removing toxin, and promoting urination can inhibit the generation of myocardial injury markers and improve hemodynamics to shorten the length of ICU stay, mitigate the TCM syndrome, and reduce the risk of death, thereby improving the prognosis of SICM.
中国医师协会急诊医师分会 , 中国研究型医院学会休克与脓毒症专业委员会 . 中国脓毒症/脓毒性休克急诊治疗指南(2018) [J]. 临床急诊杂志 , 2018 , 19 ( 9 ): 567 - 588 .
商娜 , 刘慧珍 , 王娜 , 等 . 脓毒性心肌病临床诊断评分体系的构建及效能评估 [J]. 中华危重病急救医学 , 2021 , 33 ( 12 ): 1409 - 1413 .
刘霜 , 曲东 . 脓毒性心肌病临床诊治进展 [J]. 中国小儿急救医学 , 2022 , 29 ( 1 ): 6 - 11 .
邓兆岿 , 阚诗云 , 邱占军 . 中医药治疗脓毒症心肌损伤的研究进展 [J]. 中国中医急症 , 2018 , 27 ( 7 ): 1296 - 1299 .
王东东 , 吴彦青 , 王晓鹏 , 等 . 脓毒症心肌损伤机制及中医药诊疗现状 [J]. 北京中医药 , 2018 , 37 ( 2 ): 186 - 191 .
董妍 , 董旭 , 于盼盼 , 等 . 温阳化瘀解毒法治疗脓毒症心功能障碍的临床观察 [J]. 中国实验方剂学杂志 , 2019 , 25 ( 14 ): 125 - 129 .
董妍 , 董旭 , 于盼盼 , 等 . 温阳化瘀解毒法治疗脓毒症心肌抑制的临床研究 [J]. 辽宁中医杂志 , 2019 , 46 ( 7 ): 1470 - 1473 .
L'HEUREUX M , STERNBERG M , BRATH L , et al . Sepsis-induced cardiomyopathy:A comprehensive review [J]. Curr Cardiol Rep , 2020 , 22 ( 5 ): 35 .
中国中西医结合学会急救医学专业委员会 , 《中国中西医结合急救杂志》编辑委员会 . 脓毒症中西医结合诊治专家共识 [J]. 中华危重病急救医学 , 2013 , 25 ( 4 ): 194 - 197 .
陈章宇 , 罗开源 . 不同评分系统在脓毒症预后评估中的研究进展 [J]. 中国医药导报 , 2021 , 18 ( 32 ): 42 - 45,57 .
陶丽丽 , 魏星 , 许琪 , 等 . 基于后负荷校正的心功能参数建立脓毒症心肌病患者预后的列线图预测模型 [J]. 中华危重病急救医学 , 2021 , 33 ( 11 ): 1296 - 1301 .
刘霁云 , 楚尧娟 , 师莹莹 , 等 . 血必净注射液研究现状和热点的可视化分析 [J]. 中国医院药学杂志 , 2021 , 41 ( 15 ): 1573 - 1580,1590 .
孟繁甦 , 刘勇 , 罗泽坤 , 等 . 血必净注射液对脓毒症大鼠心肌细胞凋亡保护作用的机制研究 [J]. 中国中医急症 , 2019 , 28 ( 3 ): 418 - 421 .
姚刚 , 丁艳 , 于杰 . 血必净注射液联合高压氧治疗对脓毒症心肌损伤患者血管内皮损伤及微循环的影响 [J]. 中华航海医学与高气压医学杂志 , 2021 , 28 ( 2 ): 169 - 173 .
刘霜 , 曲东 . 脓毒性心肌病临床诊治进展 [J]. 中国小儿急救医学 , 2022 , 29 ( 1 ): 6 - 11 .
SANFILIPPO F , CORREDOR C , ARCADIPANE A , et al . Tissue Doppler assessment of diastolic function and relationship with mortality in critically ill septic patients:a systematic review and meta-analysis [J]. Br J Anaesth . 2017 , 119 ( 4 ): 583 - 594 .
ZHAO C C , ZHANG L R , LIU L X , et al . Afterload-related cardiac performance predicts prognosis in critical ill patients with sepsis:A prospective observational pilot study [J]. Medicine (Baltimore) . 2021 , 100 ( 38 ): e27235 .
张灯亮 , 何先弟 , 刘杰 , 等 . PiCCO监测下的目标导向集束化治疗脓毒性休克的疗效及相关血流动力学指标对预后的诊断价值 [J]. 中国急救医学 , 2020 , 40 ( 6 ): 536 - 541 .
李欢 , 王帅 , 李楠 . 全心舒张末期容积指数及血管外肺水指数在老年心力衰竭合并脓毒性休克患者预后中的预测价值 [J]. 心脏杂志 , 2022 , 34 ( 2 ): 187 - 191,202 .
杨春燕 , 刘凤敏 , 韩梅盈 , 等 . NT-proBNP在早期评估脓毒症新生儿心功能障碍中的意义 [J]. 中华危重病急救医学 , 2020 , 32 ( 6 ): 711 - 715 .
王伟 , 刘丰芹 , 贾方兰 . 血清PCT、IL6、NT-proBNP联合hs-TnT在早期急诊脓毒症患者诊断中的临床意义 [J]. 分子诊断与治疗杂志 , 2022 , 14 ( 4 ): 643 - 646,651 .
WU Y , LIU H , WANG X . Cardioprotection of pharmacological postconditioning on myocardial ischemia/reperfusion injury [J]. Life Sci , 2021 , 264 : 118628 .
0
浏览量
32
下载量
2
CSCD
关联资源
相关文章
相关作者
相关机构
京公网安备11010802024621